TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06270706: A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination

Sponsor: Pliant Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 124 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$6,911,520

Rescue Site Savings

+$4,555,320

Unlock Full NCT06270706 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06270706 Rescue Dossier →